Brain Lower Grade Glioma: Correlation between gene mutation status and selected clinical features
(primary solid tumor cohort)
Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)
Overview
Introduction

This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.

Summary

Testing the association between mutation status of 51 genes and 6 clinical features across 168 patients, 10 significant findings detected with Q value < 0.25.

  • ATRX mutation correlated to 'AGE'.

  • IDH1 mutation correlated to 'Time to Death'.

  • CIC mutation correlated to 'HISTOLOGICAL.TYPE'.

  • TP53 mutation correlated to 'AGE',  'HISTOLOGICAL.TYPE', and 'RADIATIONS.RADIATION.REGIMENINDICATION'.

  • FUBP1 mutation correlated to 'HISTOLOGICAL.TYPE'.

  • NOTCH1 mutation correlated to 'HISTOLOGICAL.TYPE'.

  • EGFR mutation correlated to 'KARNOFSKY.PERFORMANCE.SCORE'.

  • PAX4 mutation correlated to 'AGE'.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between mutation status of 51 genes and 6 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, 10 significant findings detected.

Clinical
Features
Time
to
Death
AGE GENDER KARNOFSKY
PERFORMANCE
SCORE
HISTOLOGICAL
TYPE
RADIATIONS
RADIATION
REGIMENINDICATION
nMutated (%) nWild-Type logrank test t-test Fisher's exact test t-test Fisher's exact test Fisher's exact test
TP53 88 (52%) 80 0.101
(1.00)
6.07e-06
(0.00168)
0.276
(1.00)
0.592
(1.00)
3.08e-05
(0.00848)
0.000344
(0.0941)
ATRX 73 (43%) 95 0.124
(1.00)
0.000623
(0.168)
0.53
(1.00)
0.69
(1.00)
0.00168
(0.451)
0.019
(1.00)
IDH1 131 (78%) 37 2.4e-05
(0.00663)
0.113
(1.00)
0.0246
(1.00)
0.892
(1.00)
0.0133
(1.00)
1
(1.00)
CIC 35 (21%) 133 0.0537
(1.00)
0.437
(1.00)
0.706
(1.00)
0.535
(1.00)
1.43e-09
(3.98e-07)
0.087
(1.00)
FUBP1 19 (11%) 149 0.775
(1.00)
0.00573
(1.00)
0.806
(1.00)
0.694
(1.00)
0.000607
(0.165)
0.334
(1.00)
NOTCH1 16 (10%) 152 0.859
(1.00)
0.0196
(1.00)
0.115
(1.00)
0.111
(1.00)
0.000574
(0.156)
0.44
(1.00)
EGFR 8 (5%) 160 0.0261
(1.00)
0.00243
(0.648)
0.29
(1.00)
6.32e-11
(1.76e-08)
0.0689
(1.00)
1
(1.00)
PAX4 4 (2%) 164 0.367
(1.00)
0.000438
(0.12)
0.315
(1.00)
0.816
(1.00)
1
(1.00)
PIK3CA 15 (9%) 153 0.915
(1.00)
0.558
(1.00)
1
(1.00)
0.36
(1.00)
0.337
(1.00)
0.292
(1.00)
PIK3R1 12 (7%) 156 0.239
(1.00)
0.0323
(1.00)
0.559
(1.00)
0.696
(1.00)
0.745
(1.00)
0.773
(1.00)
PTEN 7 (4%) 161 0.194
(1.00)
0.365
(1.00)
0.463
(1.00)
0.0355
(1.00)
0.452
(1.00)
ARID1A 11 (7%) 157 0.058
(1.00)
0.794
(1.00)
0.118
(1.00)
0.353
(1.00)
0.622
(1.00)
0.547
(1.00)
TIMD4 5 (3%) 163 0.1
(1.00)
0.173
(1.00)
0.652
(1.00)
0.132
(1.00)
1
(1.00)
0.184
(1.00)
NF1 11 (7%) 157 0.0464
(1.00)
0.725
(1.00)
1
(1.00)
0.776
(1.00)
0.0514
(1.00)
0.0641
(1.00)
IDH2 6 (4%) 162 0.684
(1.00)
0.13
(1.00)
0.701
(1.00)
0.175
(1.00)
1
(1.00)
ZNF844 4 (2%) 164 0.35
(1.00)
0.997
(1.00)
1
(1.00)
0.693
(1.00)
1
(1.00)
IL32 4 (2%) 164 0.015
(1.00)
0.254
(1.00)
1
(1.00)
0.132
(1.00)
1
(1.00)
0.0445
(1.00)
TCF12 6 (4%) 162 0.972
(1.00)
0.554
(1.00)
0.085
(1.00)
0.671
(1.00)
1
(1.00)
0.418
(1.00)
ZBTB20 7 (4%) 161 0.163
(1.00)
0.64
(1.00)
0.7
(1.00)
0.488
(1.00)
0.0503
(1.00)
MUC7 4 (2%) 164 0.147
(1.00)
0.46
(1.00)
1
(1.00)
0.816
(1.00)
1
(1.00)
ZNF57 6 (4%) 162 0.247
(1.00)
0.756
(1.00)
0.404
(1.00)
0.151
(1.00)
1
(1.00)
PRAMEF11 5 (3%) 163 0.129
(1.00)
0.981
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
ANKRD30A 7 (4%) 161 0.274
(1.00)
0.0454
(1.00)
0.241
(1.00)
0.0647
(1.00)
1
(1.00)
ZNF91 5 (3%) 163 0.968
(1.00)
0.793
(1.00)
0.652
(1.00)
0.519
(1.00)
0.184
(1.00)
ZNF845 6 (4%) 162 0.347
(1.00)
0.796
(1.00)
1
(1.00)
0.885
(1.00)
0.218
(1.00)
SPDYE5 3 (2%) 165 0.00205
(0.548)
0.226
(1.00)
0.577
(1.00)
0.671
(1.00)
0.362
(1.00)
0.098
(1.00)
TPTE 6 (4%) 162 0.694
(1.00)
0.407
(1.00)
0.701
(1.00)
0.132
(1.00)
0.0149
(1.00)
0.218
(1.00)
C9ORF79 7 (4%) 161 0.389
(1.00)
0.535
(1.00)
0.463
(1.00)
0.0673
(1.00)
0.885
(1.00)
0.124
(1.00)
OR5A1 4 (2%) 164 0.17
(1.00)
0.657
(1.00)
0.636
(1.00)
0.693
(1.00)
0.624
(1.00)
NOX4 5 (3%) 163 0.483
(1.00)
0.493
(1.00)
1
(1.00)
0.735
(1.00)
1
(1.00)
DDX5 5 (3%) 163 0.157
(1.00)
0.965
(1.00)
1
(1.00)
0.398
(1.00)
0.605
(1.00)
0.664
(1.00)
PSD3 6 (4%) 162 0.959
(1.00)
0.604
(1.00)
0.404
(1.00)
0.875
(1.00)
0.575
(1.00)
0.687
(1.00)
KLKB1 5 (3%) 163 0.161
(1.00)
0.196
(1.00)
1
(1.00)
0.22
(1.00)
1
(1.00)
0.374
(1.00)
CYP2C19 3 (2%) 165 0.433
(1.00)
0.00646
(1.00)
0.261
(1.00)
0.787
(1.00)
0.249
(1.00)
OR4A16 4 (2%) 164 0.497
(1.00)
0.225
(1.00)
1
(1.00)
0.482
(1.00)
0.624
(1.00)
RPTN 5 (3%) 163 0.169
(1.00)
0.969
(1.00)
1
(1.00)
0.735
(1.00)
1
(1.00)
MYH2 7 (4%) 161 0.0858
(1.00)
0.388
(1.00)
1
(1.00)
0.132
(1.00)
0.0355
(1.00)
0.124
(1.00)
OR52B6 3 (2%) 165 0.915
(1.00)
0.8
(1.00)
1
(1.00)
0.26
(1.00)
0.598
(1.00)
SERPINB7 4 (2%) 164 0.822
(1.00)
0.19
(1.00)
0.636
(1.00)
0.574
(1.00)
0.624
(1.00)
PRDM9 5 (3%) 163 0.259
(1.00)
0.0461
(1.00)
0.652
(1.00)
0.389
(1.00)
0.374
(1.00)
ATG5 3 (2%) 165 0.849
(1.00)
0.546
(1.00)
0.577
(1.00)
0.517
(1.00)
0.626
(1.00)
1
(1.00)
C3ORF35 3 (2%) 165 0.495
(1.00)
0.724
(1.00)
1
(1.00)
1
(1.00)
0.249
(1.00)
SPRYD5 4 (2%) 164 0.403
(1.00)
0.657
(1.00)
1
(1.00)
0.0628
(1.00)
0.624
(1.00)
ZNF292 8 (5%) 160 0.725
(1.00)
0.0228
(1.00)
0.29
(1.00)
0.523
(1.00)
0.727
(1.00)
0.474
(1.00)
CREBZF 4 (2%) 164 0.722
(1.00)
0.22
(1.00)
0.315
(1.00)
0.297
(1.00)
0.482
(1.00)
1
(1.00)
MAX 4 (2%) 164 0.35
(1.00)
0.679
(1.00)
0.315
(1.00)
0.574
(1.00)
0.624
(1.00)
TPM1 4 (2%) 164 0.143
(1.00)
0.388
(1.00)
1
(1.00)
0.693
(1.00)
0.338
(1.00)
FSTL5 5 (3%) 163 0.938
(1.00)
0.634
(1.00)
1
(1.00)
0.277
(1.00)
0.374
(1.00)
C15ORF2 6 (4%) 162 0.628
(1.00)
0.379
(1.00)
0.701
(1.00)
0.33
(1.00)
0.687
(1.00)
ZNF860 4 (2%) 164 0.447
(1.00)
0.0606
(1.00)
0.636
(1.00)
0.482
(1.00)
0.624
(1.00)
OR9G9 3 (2%) 165 0.183
(1.00)
0.0207
(1.00)
1
(1.00)
0.468
(1.00)
0.249
(1.00)
'ATRX MUTATION STATUS' versus 'AGE'

P value = 0.000623 (t-test), Q value = 0.17

Table S1.  Gene #1: 'ATRX MUTATION STATUS' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 168 43.0 (13.4)
ATRX MUTATED 73 39.1 (12.6)
ATRX WILD-TYPE 95 46.1 (13.3)

Figure S1.  Get High-res Image Gene #1: 'ATRX MUTATION STATUS' versus Clinical Feature #2: 'AGE'

'IDH1 MUTATION STATUS' versus 'Time to Death'

P value = 2.4e-05 (logrank test), Q value = 0.0066

Table S2.  Gene #2: 'IDH1 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 167 46 0.0 - 211.2 (15.1)
IDH1 MUTATED 130 29 0.0 - 182.3 (17.4)
IDH1 WILD-TYPE 37 17 0.1 - 211.2 (8.4)

Figure S2.  Get High-res Image Gene #2: 'IDH1 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

'CIC MUTATION STATUS' versus 'HISTOLOGICAL.TYPE'

P value = 1.43e-09 (Fisher's exact test), Q value = 4e-07

Table S3.  Gene #3: 'CIC MUTATION STATUS' versus Clinical Feature #5: 'HISTOLOGICAL.TYPE'

nPatients ASTROCYTOMA OLIGOASTROCYTOMA OLIGODENDROGLIOMA
ALL 48 47 72
CIC MUTATED 1 3 31
CIC WILD-TYPE 47 44 41

Figure S3.  Get High-res Image Gene #3: 'CIC MUTATION STATUS' versus Clinical Feature #5: 'HISTOLOGICAL.TYPE'

'TP53 MUTATION STATUS' versus 'AGE'

P value = 6.07e-06 (t-test), Q value = 0.0017

Table S4.  Gene #4: 'TP53 MUTATION STATUS' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 168 43.0 (13.4)
TP53 MUTATED 88 38.7 (12.2)
TP53 WILD-TYPE 80 47.8 (13.1)

Figure S4.  Get High-res Image Gene #4: 'TP53 MUTATION STATUS' versus Clinical Feature #2: 'AGE'

'TP53 MUTATION STATUS' versus 'HISTOLOGICAL.TYPE'

P value = 3.08e-05 (Fisher's exact test), Q value = 0.0085

Table S5.  Gene #4: 'TP53 MUTATION STATUS' versus Clinical Feature #5: 'HISTOLOGICAL.TYPE'

nPatients ASTROCYTOMA OLIGOASTROCYTOMA OLIGODENDROGLIOMA
ALL 48 47 72
TP53 MUTATED 32 32 23
TP53 WILD-TYPE 16 15 49

Figure S5.  Get High-res Image Gene #4: 'TP53 MUTATION STATUS' versus Clinical Feature #5: 'HISTOLOGICAL.TYPE'

'TP53 MUTATION STATUS' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.000344 (Fisher's exact test), Q value = 0.094

Table S6.  Gene #4: 'TP53 MUTATION STATUS' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients NO YES
ALL 90 78
TP53 MUTATED 59 29
TP53 WILD-TYPE 31 49

Figure S6.  Get High-res Image Gene #4: 'TP53 MUTATION STATUS' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'FUBP1 MUTATION STATUS' versus 'HISTOLOGICAL.TYPE'

P value = 0.000607 (Fisher's exact test), Q value = 0.16

Table S7.  Gene #5: 'FUBP1 MUTATION STATUS' versus Clinical Feature #5: 'HISTOLOGICAL.TYPE'

nPatients ASTROCYTOMA OLIGOASTROCYTOMA OLIGODENDROGLIOMA
ALL 48 47 72
FUBP1 MUTATED 1 2 16
FUBP1 WILD-TYPE 47 45 56

Figure S7.  Get High-res Image Gene #5: 'FUBP1 MUTATION STATUS' versus Clinical Feature #5: 'HISTOLOGICAL.TYPE'

'NOTCH1 MUTATION STATUS' versus 'HISTOLOGICAL.TYPE'

P value = 0.000574 (Fisher's exact test), Q value = 0.16

Table S8.  Gene #8: 'NOTCH1 MUTATION STATUS' versus Clinical Feature #5: 'HISTOLOGICAL.TYPE'

nPatients ASTROCYTOMA OLIGOASTROCYTOMA OLIGODENDROGLIOMA
ALL 48 47 72
NOTCH1 MUTATED 1 1 14
NOTCH1 WILD-TYPE 47 46 58

Figure S8.  Get High-res Image Gene #8: 'NOTCH1 MUTATION STATUS' versus Clinical Feature #5: 'HISTOLOGICAL.TYPE'

'EGFR MUTATION STATUS' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 6.32e-11 (t-test), Q value = 1.8e-08

Table S9.  Gene #20: 'EGFR MUTATION STATUS' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

nPatients Mean (Std.Dev)
ALL 88 88.3 (10.5)
EGFR MUTATED 4 80.0 (0.0)
EGFR WILD-TYPE 84 88.7 (10.6)

Figure S9.  Get High-res Image Gene #20: 'EGFR MUTATION STATUS' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'PAX4 MUTATION STATUS' versus 'AGE'

P value = 0.000438 (t-test), Q value = 0.12

Table S10.  Gene #39: 'PAX4 MUTATION STATUS' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 168 43.0 (13.4)
PAX4 MUTATED 4 31.5 (3.0)
PAX4 WILD-TYPE 164 43.3 (13.4)

Figure S10.  Get High-res Image Gene #39: 'PAX4 MUTATION STATUS' versus Clinical Feature #2: 'AGE'

Methods & Data
Input
  • Mutation data file = LGG-TP.mutsig.cluster.txt

  • Clinical data file = LGG-TP.clin.merged.picked.txt

  • Number of patients = 168

  • Number of significantly mutated genes = 51

  • Number of selected clinical features = 6

  • Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)